title: [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
abstract: In this study, it is to compare the effectiveness of prevention against and treatment of doxorubicin (DOX) induced cardiotoxicity by dexrazoxane and schisandrin B (Sch B) in rats. Sprague-Dawley (SD) rats were randomly divided into the following 6 groups: normal saline group, DOX group, DOX+DEX group, DOX+Sch B (80 mg x kg(-1)) group, DOX+Sch B (40 mg x kg(-1)) group and DOX+Sch B (20 mg x kg(-1)) group. The results showed that Sch B could combat the increase of myocardial enzymes in peripheral blood, decrease of the enzyme activity of myocardial tissue antioxidant enzymes and disorders of systolic and diastolic function of heart in rats intravenously injected with doxorubicin (15 mg x kg(-1)). Sch B was better than DEX in protecting rat against DOX-induced the symptoms. Sch B could protect rat against DOX-induced acute cardiomyopathy and has clinical potential applications.
authors.forename: Kai-Yong
authors.initials: KY
authors.lastname: Hu
authors.forename: Yong
authors.initials: Y
authors.lastname: Yang
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: He
authors.forename: Duo-Wei
authors.initials: DW
authors.lastname: Wang
authors.forename: Zhi-Rong
authors.initials: ZR
authors.lastname: Jia
authors.forename: Shu-Ran
authors.initials: SR
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Tian
authors.forename: Jie
authors.initials: J
authors.lastname: Mao
authors.forename: Xian-Jing
authors.initials: XJ
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000975:Antioxidants / Q000378:metabolism; D009202:Cardiomyopathies / Q000139:chemically induced / Q000188:drug therapy; D066126:Cardiotoxicity / Q000188:drug therapy*; D034242:Cyclooctanes / Q000627:therapeutic use; D064730:Dexrazoxane / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects*; D006321:Heart / Q000503:physiopathology; D017705:Lignans / Q000627:therapeutic use*; D009206:Myocardium / Q000201:enzymology; D011083:Polycyclic Compounds / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D034242:Cyclooctanes; D017705:Lignans; D011083:Polycyclic Compounds; C015499:schizandrin B; D064730:Dexrazoxane; D004317:Doxorubicin